Briefing.com uses cookies to store information on your computer that is essential to making the site work and to customizing the user experience. By using the site, you consent to the placement of these cookies. Read our cookie policy to learn more and how to withdraw your consent.     
You must subscribe to access archives older
than one year.
Take a free trial of Briefing In Play® now.
Subscribe Here
TERMS OF USE

The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.com’s RSS service. The use of the RSS service is also subject to the terms and conditions of the Briefing.com Reader Agreement which governs the use of Briefing.com's entire web site (www.briefing.com) including all information services. These Terms of Use and the Briefing.com Reader Agreement may be changed by Briefing.com at any time without notice.

Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for use by individuals, as long as the feeds are used for such individual’s personal, non-commercial use. Any other uses, including without limitation the incorporation of advertising into or the placement of advertising associated with or targeted towards the RSS Content, are strictly prohibited. You are required to use the RSS feeds as provided by Briefing.com and you may not edit or modify the text, content or links supplied by Briefing.com. To acquire more extensive licensing rights to Briefing.com content please review this page.

Link to Content Pages:
The RSS service may be used only with those platforms from which a functional link is made available that, when accessed, takes the viewer directly to the display of the full article on the Briefing.com web site. You may not display the RSS content in a manner that does not permit successful linking to, redirection to or delivery of the applicable Briefing.com web site page. You may not insert any intermediate page, “splash” page or any other content between the RSS link and the applicable Briefing.com web site page.

Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS content, and any and all Briefing.com logos and trademarks used in connection with the RSS service. You are required to provide appropriate attribution to the Briefing.com web site in connection with your use of the RSS feeds. If you provide this attribution using a graphic we require you to use the Briefing.com web site logo that we have incorporated into the Briefing.com RSS feed.

Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any or all of the RSS feeds at any time and to require you to cease displaying, distributing or otherwise using any or all of the RSS feeds for any reason including, without limitation, your violation of any provision of these Terms of Use or the terms and conditions of the Briefing.com Reader Agreement. Briefing.com assumes no liability for any of your activities in connection with the RSS feeds or for your use of the RSS feeds in connection with your web site.

Briefing.com
Subscribers Log In
 
  • HOME
  • OUR VIEW
    • Page One
    • The Big Picture
  • ANALYSIS
    • Premium Analysis
    • Story Stocks
  • MARKETS
    • Stock Market Update
    • Bond Market Update
    • Market Internals
    • After Hours Report
    • Weekly Wrap
  • CALENDARS
    • Upgrades/Downgrades
    • Economic
    • Stock Splits
    • IPO
    • Earnings
    • Conference Calls
    • Earnings Guidance
  • EMAILS
    • Edit My Profile
  • LEARNING CENTER
    • About Briefing.com
    • Ask An Analyst
    • Analysis
    • General Concepts
    • Strategies
    • Resources
    • Video
  • COMMUNITY
    • Twitter
    • Facebook
    • LinkedIn
    • YouTube
    • Google+
  • SEARCH
Login | Archive | EmailEmail |
HOME > Analysis >Story Stocks >Agilent: Investors twiddling...
Story Stocks® Archive
Last Update: 15-Aug-18 11:01 ET
Agilent: Investors twiddling their thumbs after in-line results, guidance (A)
After matching market expectations for third quarter sales and giving in-line guidance, shares of Agilent (A 64.78, -1.97, -2.95%) trade lower, though all indications are that tariff impacts on Agilent could be manageable.

All told, third quarter earnings per share (EPS) of $0.67 and revenue growth of 8% to $1.20 bln were in-line with what the Street had expected. Agilent also delivered adjusted operating margins of 22.6%, an increase of 110 basis points from a year ago.

Breaking it down by segment, Agilent saw core growth of 8% in its pharma segment, managing a strong showing even while facing a tough quarter for comparison in the form of last year’s 10% Q3 growth. The company sees strength across all its business groups in this segment and applauds particularly strong performances in mass spectrometry, cell analysis, CrossLabs consumables and services, and genomics.

Chemical and energy markets revenue, meanwhile, was up 12% against a difficult prior-year compare of 10%. The company reports that ongoing market investment has continued to remain positive even with the strain and uncertainty of tariff rhetoric and retaliatory policies. The company thanks performance China and Europe for leading the overall global growth.

Revenue growth of 3% in academia and government was in line with expectations. Strong performance from cell analysis, molecular spectroscopy, ICP-MS and CrossLabs services and consumables drove results in the segment. Notably, China and the rest of Asia have delivered double-digit growth in this end market.

Diagnostics and clinical revenue grew 5%. Genomics and the company’s Reagent Partnership business contributed strength, offsetting continued challenges in the U.S. Pain Management market. Food revenue declined 1%, strength in the Americas offset by declines in Europe versus a tough compare of 35% growth rate last year, and, as expected, China instrument sales were also down this quarter. Environmental forensics was flat in Q3, while forensics growth was offset by the expected temporary slowing of instrument sales in China environmental. Still, big picture, the company sees its overall China business as strong, noting that it saw growth of 10% in the quarter.

In terms of guidance, Agilent expects Q4 revenues of $1.24-1.26 bln and EPS of $0.72-0.74. FX is projected to have a negative impact of $21 mln on revenue and $2 mln on the operating profit. The company’s 23.6% adjusted operating margin at midpoint will be up 100 basis points sequentially and up 30 basis points on a year/year basis even after funding the Lasergen R&D.

Further, the increase in tariffs, effective early July, is expected to have a negative impact of $3.5 mln as the company has initiated actions to its supply chain. When those actions are completed in mid-2019, Agilent expects the net annualized impact to be around $9 mln excluding potential pricing actions.

For the full year 2018, revenue growth is projected at 6.1% at the midpoint on a core basis or 60 basis points over the previous guidance. The company’s FY18 revenue guidance of $4.86-4.88 bln is $10 mln over previous guidance, including $22 mln due to the acquisition of AATI, ULTRA Scientific, and ProZyme, with currency having a negative impact of $32 mln. The company’s EPS guidance of $2.69-2.71 ($2.70 at midpoint) is up $0.05 on previous guidance and corresponds to a 14% year/year increase. Adjusted operating margin for the year is expected to be 22.6%, or 60 basis point higher than was achieved in fiscal year 2017. Lastly, the company’s core operating margin incremental is expected to be 39% for the fiscal year, at the high end of its operating model.

Investors have shown a bit of a ho-hum reaction to Agilent’s report. Perhaps something of a wait-and-see attitude is prevailing as investors watch for the company to continue to execute on its FY18 plan. Shares trade between the 200-day simple moving average (67.17) and the 50-day (64.36), holding a nearly 2.4% loss on the year. The stock has been strong recently, though, up 5.7% since the start of July.
After matching market expectations for third quarter sales and giving in-line guidance, shares of Agilent (A 64.78, -1.97, -2.95%) trade lower,
 
Add this to my Page Alerts.
MARKET PLACE
SPONSORED LINKS
 
  Follow Us On Linkedin  
 
 
LOGIN

CONTACT US
Support
Sitemap
PREMIUM SERVICES
Take a Tour
Compare Services
Request a Demo
INSTITUTIONAL SALES
ADVERTISING

CONTENT LICENSING

EMAILS & NEWSLETTERS
ABOUT US
Our Experts
Management Team

COMMUNITY
MEDIA
Events
News
Awards
PRIVACY STATEMENT
Cookie Policy
Reader Agreement
Policies
Disclaimer
Copyright © Briefing.com, Inc. All rights reserved.
Close
You must log in or register to access this area.
Tip of the Day
Virtual Url Page Popup